Echo IQ – EchoSolv AS Enters Mount Sinai Health System
- Noel Ong
- Apr 30
- 7 min read
Updated: 5 days ago
EchoSolv AS Enters Mount Sinai Health System: A Deployment Inside One of the United States' Leading Cardiovascular Networks
Samso News | ASX: EIQ | Source: Echo IQ Limited ASX Release, 28 April 2026
Samso has been following the Echo IQ since September 2025. The research that went into preparing for the first Coffee with Samso with Dustin Haines was the eye opener for myself. It became very clear that this was a business that just needed validation and the first was the FDA submission which I now understand is not something that is caually done. The proecess and the acceptance of the request for approval in itself was a strenous process and is almost a tick of approval on acceptance for the requrest.
It was at that stage that my thoughts was that this is a matter of time and not a need for pprove of concept. The acceptance for partnership or acceptance of their product into the Mayo Clinic and now the Mount Sinai system is the ebst validation that I can think of, in my humble opinion anyway.
The product targets severe aortic stenosis — a condition that carries meaningful consequences when it goes undetected. The commercial model is predicated on integration into existing echocardiography workflows rather than requiring new infrastructure, which reduces the barrier to adoption inside hospital systems. The Mount Sinai engagement confirms that leading cardiovascular institutions are willing to put this software into active clinical use.
Echo IQ Limited (ASX: EIQ) has confirmed the deployment of EchoSolv AS into Mount Sinai Health System, a major healthcare network based in New York, United States. This announcement represents the company's most significant US institutional placement to date. Mount Sinai Health System operates seven hospitals, more than 400 outpatient practices, and over 3,760 beds across its campuses. Its affiliate, the Icahn School of Medicine at Mount Sinai, is a globally recognised medical school.
The system services millions of patient interactions each year and is consistently positioned among the top hospital networks in the United States across multiple clinical specialties, with cardiology and heart surgery among its most prominent areas.
The significance of this deployment is grounded in the specific ranking of Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital. According to U.S. News & World Report's 2025–26 Best Hospitals rankings, it holds the No. 1 position in New York and No. 2 in the nation for Cardiology, Heart and Vascular Surgery. For a company commercialising AI-based decision support software for the assessment of severe aortic stenosis, placing that product inside the second-ranked heart hospital network in the United States is a measurable step in its stated US commercial strategy.
Severe aortic stenosis is a condition in which narrowing of the aortic valve restricts blood flow from the heart. It can go undetected or be inconsistently assessed in high-volume clinical environments, and when left untreated, patients cannot benefit from the therapeutic options available. EchoSolv AS is designed to operate as an adjunct within existing echocardiography workflows, providing a measurement-based second review to assist physicians in identifying cases that may otherwise be missed. The software is not intended to replace physician judgment but to augment the assessment process.
Management Commentary - Echo IQ and EchoSolv AS
What the Company's Leadership Said About the Mount Sinai Deployment
Nick Lubbers, US President and General Manager of Echo IQ, addressed the strategic context of the deployment. He described the engagement as an important step in the company's US commercial growth, noting that it reflects increasing interest from cardiologists in tools that can support assessment within routine echocardiography workflows. Lubbers characterised EchoSolv AS as a practical, measurement-based second look for physicians assessing severe aortic stenosis, and stated the company intends to demonstrate the product's utility at scale through its work with Mount Sinai Health System. He also framed the Mount Sinai engagement as consistent with Echo IQ's broader trajectory of building partnerships with leading hospitals and expanding access to AI-enabled decision support in cardiology.
"Mount Sinai is the kind of institution that helps set the standard for clinical excellence and innovation."
— Nick Lubbers, US President and General Manager, Echo IQ Limited
Clinical commentary was provided by Dr. Stamatios Lerakis MD, PhD, Director of the Cardiovascular Imaging Program and Imaging for Structural and Valve Interventions for Mount Sinai Health System. Dr. Lerakis noted that EchoSolv AS can highlight cases of aortic stenosis that may otherwise be under-diagnosed and remain untreated, meaning affected patients would not benefit from the therapeutic advances available in the management of aortic valve disease. He described the software as an adjunct for the echocardiographer, confirming that the physician retains final interpretive authority, and stated that the product would strengthen patient care.
"This product can highlight patients with aortic stenosis that can be otherwise under-diagnosed, remain untreated and as a result, not benefit from the tremendous therapeutic advancements in the space of aortic valve diseases."
— Dr. Stamatios Lerakis MD, PhD, Director Cardiovascular Imaging Program, Mount Sinai Health System
Disclosure noted in the ASX release: Dr. Stamatios Lerakis serves as a paid key opinion leader, speaker, and advisory board member for Echo IQ Limited.
Near-Term Milestones to Watch
What Investors Should Monitor Following This Deployment Announcement
Samso Concluding Comments
Putting the Mount Sinai Deployment in Context
To say that the deployment of EchoSolv AS into Mount Sinai Health System is a significant step for Echo IQ would be an understatement. The relevance of the institution is well documented in the medical profession and the narrative of importance whenever you hear thatat some person of significance has been admited to a Mt. Sinai hospital,
To the intiated, this hospital system may be ranked second in the nation for cardiology and heart surgery by U.S., however to the "nomral people, the everday population, the mention of Mt. Sinai represents the upper tier of the US without stipulating the cardiovascular landscape.
For Echo IQ Limited with a product designed specifically for cardiologists operating within echocardiography workflows, gaining access to a system of this standing reflects the product's ability to meet the standards required by a top-level clinical institution.
Shareholders should be sitting back rubbing their hands already knowing that the ASX release uses the language of deployment, which denotes active clinical use.
For now, I think that Echo IQ Limtied is enjoying the spotlight of good compnay stories on the ASX.
Previous Samso News Coverage
Samso has followed Echo IQ across multiple ASX releases. The following represents our prior published coverage of the company:
April 16, 2026 -
March 26, 2026 -
January 30, 2026 -
December 15, 2025 -
November 26, 2025 -
October 25, 2025 -
September 7, 2025 -
About Echo IQ
Echo IQ Limited (ASX: EIQ) — AI-Driven Decision Support in Cardiology
Echo IQ is a Sydney-based AI and medical technology company. Its lead product, EchoSolv AS, is an AI-based decision support software indicated as an adjunct to echocardiography for the assessment of severe aortic stenosis. The software is designed to be used by qualified healthcare professionals alongside existing clinical tools, providing a measurement-based review to assist physicians in identifying cases of severe aortic stenosis that may otherwise go undetected.
EchoSolv AS holds FDA 510(k) clearance in the United States. The company's commercial strategy centres on deploying the software at high-volume cardiovascular institutions and cardiology practices across the US market.
The Samso Way – Seek the Research
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Never bite off more than you can chew is my parting comment.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insigh0ts from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
.
---
Comments